30 Nov Cellular Logistics Announces Promising Pre-clinical Heart Study Results
MADISON, WI, November 23, 2021 – Cellular Logistics, a Madison-area company that is creating a new way to restore heart function and help patients with heart damage announces promising early data using its Tandem™ biomatrix technology. Investigators at the University of Wisconsin-Madison, led by Drs. Eric Schmuck, Timothy Kamp, and Amish Raval reported the initial results of their NIH-funded study entitled ‘Human Induced Pluripotent Stem Cell-Derived Committed Cardiac Progenitor Cells (CCPs) Engraft and Differentiate Following Transendocardial Injections in a Swine Ischemic Heart Failure’ at the 2021 American Heart Association Scientific Sessions. Dr. Raval, an Associate Professor of Medicine and Biomedical Engineering at the University of Wisconsin-Madison, presented exciting top-line data showing that catheter delivery of CCPs combined with Cellular Logistics’ Tandem™ technology was associated with human cell grafts at 2 weeks and 1 month following injection in a pig ischemic heart failure model. He stated that “this was a particularly challenging animal study given the number of animals that succumbed to infection complications due to the immunosuppression regimen, but despite this, there were interesting initial trends toward improved ejection fraction and stroke volume in the CCP treated animals.” Ongoing work is underway to characterize these grafts and evaluate whether Tandem boosts graft formation and CCP differentiation into cardiac cells in vivo. Dr. Kamp added that “these are encouraging findings given that injecting CCP’s, Tandem, or both in combination were not associated with malignant ventricular tachycardia or sudden death – a finding that has plagued prior large animal studies transplanting human pluripotent stem cell-derived cardiomyocytes.” The investigators are also actively analyzing the invasive pressure-volume loop data, which were not available at the time of the presentation. As described by Dr. Schmuck, Cellular Logistics’ Chief Scientific Officer, “the P-V loop data will give additional insight on the functional response of CCPs and Tandem on contractility reserve. Completion of this large animal study is a critical milestone for the 3-way academic and industry collaboration between Cellular Logistics, Fujifilm Cellular Dynamics, and the University of Wisconsin.” For Immediate Release 2
About Cellular Logistics
Cellular Logistics, Inc. is dedicated to improving the lives of individuals suffering from cardiovascular disease. CL was founded in 2016 by a multi-disciplinary clinical and scientific team from the University of Wisconsin-Madison School of Medicine and Public Health. The company vision is to help create a world where a new generation of therapies can reverse the debilitating symptoms of heart failure; dramatically reducing re-hospitalization and enabling patients to live longer, healthier lives. Its product, Tandem™, holds the promise of revitalizing a damaged heart and creating unique combined therapeutic approaches for the world’s leading cause of death. Located in Madison, Wisconsin, CL resides in one of the premier scientific ecosystems in the world for cell therapy and regenerative medicine.
Press Contact: Alex Vodenlich, alex@cellogistics.com